This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Infectious disease				
Influenza	Influenza A virus hemagglutinin (HA)	<i>In vitro</i> and mouse studies suggest that vaccination using a partially glycosylated version of the viral HA antigen could help prevent influenza infection. <i>In vitro</i> , antibodies targeting partially glycosylated HA had better binding affinity and neutralization activity against influenza viral subtypes than antibodies targeting fully glycosylated HA. In mice, partially glycosylated HA led to better survival following viral challenge than the fully glycosylated form. Next steps include further testing in animals. Vaxart Inc. and VaxInnate Corp. have influenza vaccines targeting HA in preclinical and Phase I testing, respectively.	Patent application filed in U.S.; licensed to Opko Health Inc.	Wang, C. <i>et al. Proc. Natl. Acad. Sci. USA</i> ; published online Oct. 12, 2009; doi:10.1073/pnas.0909696106 Contact: Chi-Huey Wong, Academia Sinica, Taipei, Taiwan e-mail: chwong@gate.sinica.edu.tw or wong@scripps.edu
SciBX 2(41); doi:10.1038/scibx.2009.1534 Published online Oct. 22, 2009				